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A Three-Hybrid Approach to Scanning the Proteome
for Targets of Small Molecule Kinase Inhibitors
laborious and time consuming. Furthermore, the cloning
of cDNAs encoding candidate targets is uncoupled from
the target identification process. Several functional
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Carsten Degenhart,1 Sabine Baumann,1 cloning methods have been developed in recent years to
circumvent these problems. These include yeast three-Wolfgang Wallner,1 Andrea Huber,1
Severine Dedier,1 Simone Dill,1 hybrid (Y3H) [1], drug-western [2], phage display cloning
[3], and mRNA display cloning [4]. All of these methodsDavid Kinsman,2 Mark Hediger,2
Nicholas Bockovich,2 Sebastian Meier-Ewert,1,2 link the identification of ligand binding proteins to the
selection of cDNAs encoding these proteins. The Y3HArthur F. Kluge,2 and Nikolai Kley1,2,*
1GPC Biotech AG system distinguishes itself from the other methods in
that the interaction between a small molecule and a20 Fraunhoferstrasse
Planegg/Martinsried 82152 target protein occurs in intact cells rather than in vitro.
Y3H is based on the yeast two-hybrid system (Y2H),Germany
2 GPC Biotech Inc. which has proven to be a powerful tool for detecting
protein-protein interactions [5–7]. Adaptation of Y2H to610 Lincoln Street
Waltham, Massachusetts 02451 Y3H required the use of small molecule hybrid ligands,
sometimes also referred to as chemical inducers of di-
merization (CIDs) or “dimerizers” [8]. CIDs have been
widely used to crosslink (“dimerize”) at will proteins inSummary
living cells that have been engineered to express hybrid
proteins with appropriate ligand binding and signalingIn this study, we explored the application of a yeast
three-hybrid (Y3H)-based compound/protein display domains (three-hybrid systems). In this manner, numer-
ous biological processes, such as activation of specificsystem to scanning the proteome for targets of kinase
inhibitors. Various known cyclin-dependent kinase signaling pathways, protein subcellular localization, or
gene expression, were placed under the control of(CDK) inhibitors, including purine and indenopyrazole
analogs, were displayed in the form of methotrexate- chemical dimerizers [8–10]. In contrast, small molecule
hybrid ligands can be used in Y3H to identify and charac-based hybrid ligands and deployed in cDNA library
or yeast cell array-based screening formats. For all terize small molecule-protein interactions.
Liu and colleagues first described the Y3H systeminhibitors, known cell cycle CDKs as well as novel
candidate CDK-like and/or CDK-unrelated kinase tar- and its application to screening of cDNA libraries for
target discovery [1]. An engineered glucocorticoid re-gets could be identified, many of which were indepen-
dently confirmed using secondary enzyme assays and ceptor (GR) protein was used as a DNA-bound docking
platform to display a dexamethasone (DEX)-tetheredaffinity chromatography. The Y3H system described
here may prove generally useful in the discovery of FK506 hybrid ligand to target proteins that could acti-
vate reporter gene expression upon binding. FKBP12,candidate drug targets.
a known target of FK506, was identified, indicating that
Y3H could be a valuable tool for the identification ofIntroduction
novel small molecule-protein interactions, at least in
principle. Despite this first promising report on Y3H andOrganic small molecules have been widely used as cell
permeable ligands to elucidate mechanisms of signal the broad uses of Y2H for mapping protein-protein inter-
actions, only very few studies have subsequently madetransduction and as therapeutic agents. The majority of
small molecule drugs elicit their pharmacological action use of Y3H for the characterization of small molecule-
protein interactions [11–14]. Only one other study madethrough binding to protein targets. The identification
of such targets is of fundamental importance to our use of Y3H in screening cDNA libraries for target identifi-
cation [14], reporting the successful identification (“re-understanding of the molecular basis of drug action
discovery”) of dihydrofolate reductase (DHFR) as a tar-and of mechanisms underlying drug efficacy and side
get of methotrexate (MTX) when using MTX as the “bait”effects.
tethered to DEX. Whether Y3H is suitable for the detec-Traditionally, the identification of receptors for small
tion of weaker and novel interactions (FK506 and MTXmolecules has relied on in vitro biochemical methods,
display affinities for FKBP12 and DHFR in the nanomolarsuch as photo-crosslinking, radiolabeled ligand binding,
to picomolar range, respectively) and is amenable toand affinity chromatography. Recent technological ad-
hybrid ligands incorporating different types of organicvances in protein separation and analytical methods
small molecules, e.g., enzyme inhibitors, remained un-have significantly improved affinity chromatography-
clear.based approaches for the detection of small molecule-
In the present study, we set out to explore in moreprotein interactions. However, these approaches remain
detail the potential and limitations of Y3H for the identifi-
cation of novel small molecule protein targets, with em-*Correspondence: nikolai.kley@gpc-biotech.com
phasis on the characterization of the target spectrum3 Current address: Vertex Pharmaceuticals, Cambridge, Massachu-
setts 02139. of ATP-competitive active site kinase inhibitors. More
Chemistry & Biology
212
Figure 1. Y3H Assay System
(A), Y3H system components; (B), illustration
of the general MFC synthesis strategy using
purvalanol B as an example. Details of chemi-
cal synthesis are described in Experimental
Procedures (see Supplemental Data).
than 500 putative kinases are encoded by the human polyethylene glycol spacer (or linker). (2) A DNA binding
genome, and they play a central role in the regulation hybrid protein consisting of a LexA DNA binding domain
of multiple cellular processes and diseases [15]. Two (LexA-DBD) fused to dihydrofolate reductase (DHFR),
hundred forty-four kinases map to disease loci or cancer as described previously [11–13]. (3) A second hybrid
amplicons [15]. Thus, methods that would support the protein consisting of a transcriptional activation domain
identification of the target spectrum of kinase inhibitors (AD) derived from the yeast transcription factor GAL4
could have an impact on drug discovery across diverse fused to a polypeptide (Y) potentially capable of binding
therapeutic areas. Here, we describe the successful im- to the test compound of interest. Compound-mediated
plementation of versatile screening approaches with a recruitment of the AD-fusion protein to the proximity
Y3H system that employs MTX-based hybrid ligands of the promoter region of an integrated reporter gene
and the identification of novel candidate targets for vari- induces reporter gene expression. In this study, we re-
ous widely used cyclin-dependent kinase inhibitors with lied mostly on the use of a reporter gene encoding HIS3,
antitumor activity. an auxotrophic marker widely used in various Y2H sys-
tems. Expression of HIS3 enables yeast cells to grow
in the absence of histidine in the culture medium,Results
allowing for easy and sensitive detection of a hybrid
ligand-induced interaction event.The Y3H Assay System
Figure 1B shows an example of the synthesis of aFigure 1A highlights the three major components of the
kinase inhibitor MFC used in this study, GPC286076Y3H system used in this study. (1) A hybrid ligand, here
(purvalanol B-MFC). We found that use of a PEG-spacernamed methotrexate fusion compound (MFC), which is
yielded MFCs with good water solubility properties. Thiscomposed of a methotrexate “anchor” moiety coupled
to a small molecule test compound (SM) of interest via a facilitates an even diffusion of compound through agar
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and more uniform and robust growth of affected yeast hybrid ligand GPC285937 (a DEX-MFC) and MTX-5PEG-
OCH3, a “universal control” compound that containsclones. PEG-spacers containing three or more ethyl-
eneglycol subunits were found necessary for good per- methotrexate and PEG moieties but lacks a test com-
pound (Figure 2A). All MFCs derived from the CDK inhibi-formance in Y3H (data not shown). Test experiments
using the DEX-derived MFC, GPC285937 (Figure 2A), tors retained CDK inhibitory activity (data not shown).
Relative cellular uptake and binding of the MFC hybridshowed strong reporter expression (HIS3 or an alterna-
tive reporter, LacZ) in the presence of a GR-AD fusion ligands to the LexA-DHFR hybrid protein in cells were
indirectly determined by competition experiments. Aprotein (data not shown), consistent with previous stud-
ies in which MTX-DEX hybrid ligands incorporating dif- “reference MFC” with known target binding properties
was used to activate HIS3-reporter gene expression (seeferent chemical spacers were employed [11–13].
Experimental Procedures for details). The ability of a
test MFC to compete via its MTX moiety with the refer-
Synthesis of Kinase Inhibitor Hybrid Ligands ence MFC for binding to LexA-DHFR was assayed as a
Our interest in cell cycle control led us to select well- function of a decrease in HIS3 reporter expression (yeast
characterized CDK inhibitors to explore the use of ATP- cell growth) in response to increasing concentration of
competitive kinase inhibitors in Y3H and to evaluate the the test MFC. Similar assays have been described for
potential of Y3H for identifying novel small molecule- measuring relative uptake of FK506-analog (AP1867) hy-
protein interactions. Purines are widely studied CDK brid ligands by mammalian cells [31]. As shown in Figure
kinase inhibitors with antiproliferative activities [16–18]. 2B, MFCs incorporating either purvalanol B or roscovi-
The purine purvalanol B is a nanomolar inhibitor of tine (GPC286076 and GPC286077) competed nearly
CDK1, CDK2, and CDK5 (Figure 2A; [19]). Recent protein equally well, as did the control compounds MTX-5PEG-
binding studies revealed additional kinase targets for OCH3 and GPC285937. IP-1 and IP-1* MFCs (GPC286026
this inhibitor, including casein kinase 1 (CK1), ERK1, and GPC286060) showed a competition profile compa-
and ERK2 [20, 21]. Purvalanol B was reported to inhibit rable to that of the other MFCs in a different set of
these latter targets with IC50 values in the micromolar experiments (data not shown). In summary, no signifi-
range. (R)-Roscovitine (also known as CYC202), a re- cant differences were observed for these compounds,
lated purine analog [17, 22], exhibits antitumor activity facilitating comparative interaction analysis, as de-
in vivo and is currently in phase I/II clinical trials as an scribed below.
anticancer agent [23, 24]. Compared to purvalanol B, it
is a moderate inhibitor of CDK1, CDK2, and CDK5 (Fig-
ure 2A) [25, 26]. No other targets for roscovitine have Identification of Novel Targets for the Purine
Analog Purvalanol Bbeen reported to our knowledge. Indenopyrazoles are
a structurally different class of kinase inhibitors, with an Figure 3A outlines the cDNA library screening strategy
pursued for target identification with the purvalanoloverlapping but distinct CDK inhibition profile. Various
indenopyrazoles have been reported to be potent, nano- B-MFC. As shown, all candidate targets identified in
cDNA library screens were routinely subjected to a fol-molar inhibitors of CDK1, CDK2, and CDK4 [27–29]. Sim-
ilarly, IP-1 (Figure 2A) is a potent inhibitor of CDK1, low-up analysis. This consisted of retransformation of
yeast strains with the individually identified cDNA clonesCDK2, and CDK4, and it displays potent antiproliferative
activity against tumor cells in vitro, with IC50 values in and subsequent interrogation of a robotically generated
recombinant yeast cell array with test MFC and controlthe low nanomolar range (data not shown).
For the design of the purvalanol B-MFC, GPC286076 compounds (we refer to this as yeast halo-analysis). In
addition, kinase clones that were otherwise indepen-(Figure 2A), a suitable attachment site for the spacer was
derived from the CDK2-purvalanol B crystal structure, dently cloned or identified in Y3H screens with com-
pounds other than purvalanol B were used to generatewhich suggested that attachment to the carboxylic acid
of the 6-anilino substituent of the inhibitor would not recombinant yeast strains that were included in the rep-
lica spotting of arrays. As discussed below, analysisinterfere with its interaction with the kinase [16, 20, 30].
As a control, we synthesized a CDK-inactive N6-methyl- of such an extended array led to the identification of
additional candidate purvalanol B binders and facilitatedated purvalanol B (Me-Purvalanol B)-MFC, GPC286207
(Figure 2A). Replacement of the N6 hydrogen, which a more thorough comparative analysis using a diverse
set of MFCs derived from other kinase inhibitors. Interro-forms a key hydrogen bond with Leu83 of CDK2, with
a methyl group was shown to greatly reduce the CDK- gation of replica arrays was performed at a high and low
dose of MFCs. Spotting of a high amount of compoundinhibitory activity of purvalanol B as well as its ability to
bind to other kinases [20]. The chemical structures of translated into an estimated concentration of compound
in the yeast halo-analysis that is comparable to thatthe roscovitine-MFC (GPC286077) and the indenopyra-
zole IP-1-MFC (GPC286026) are also shown in Figure used in the purvalanol B cDNA library screens. Spotting
of a low amount served the purpose of annotating tar-2A. The rationale for selecting the PEG-spacer attach-
ment site for these two inhibitors was also derived from gets that yielded signals at significantly lower concen-
tration of compound (10-fold lower). Figure 3B shows apublished human CDK2-inhibitor complex crystal struc-
tures and, in the case of IP-1, also structure-activity- representative result obtained by interrogating a yeast
cell array representing a panel of kinases with com-relationship information on indenopyrazoles [22, 27–29].
IP-1* is a close structural variant of IP-1 but lacks CDK- pounds at the high dose. The left panel in Figure 3B
summarizes array results obtained with candidate tar-inhibitory activity (Figure 2A). The IP-1*-MFC, GPC286060,
was used as a Y3H control compound along with the gets identified in cDNA library screens with purvalanol
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Figure 3. Y3H Identification of Kinase Inhibitor Targets
(A) Y3H cDNA library screening workflow as utilized with purvalanol B-MFC. Screening of a cDNA library involved the following: (1) transformation
of LexA-DHFR-expressing yeast cells with a cDNA library of choice, (2) selection for transcriptional expression of the HIS3 auxotrophic marker
in the presence of an MFC (reflected by yeast cell growth in absence of histidine), (3) selection/picking of positive colonies, (4) robotic arraying
of these yeast cells and reconfirmation of compound dependence of HIS3-reporter expression, (5) plasmid isolation and sequencing, (6)
retransformation of yeast expressing LexA-DHFR with purified plasmids, (7) robotic arraying of the transformed yeast cells, and (8) reconfirmation
of specific HIS3-reporter activation by the test MFC using a series of genetic or compound-based counterscreens. The genetic counterscreens
involved tests assaying for dependency of a seemingly positive interaction event on the presence of both the LexA-DHFR and AD-fusion
proteins (the concept of genetic counterscreening is described in [40]). The compound-based counterscreens involved tests assaying the
specificity of an interaction by comparing HIS3-reporter activation in response to test MFC versus control MFCs. All of these steps were
found to be necessary for the identification of candidates with a high likelihood of encoding bona fide small molecule binding proteins. Replica
yeast cell arrays of 96-well format (generally more sensitive than random cDNA library screens, see below) were also used to simultaneously
interrogate an additional set of cloned kinases with the MFCs.
(B) Array-based interaction analysis (halo-analysis) of a series of kinases that were either identified in purvalanol B cDNA library screens (left
panel) or otherwise independently cloned (right panel). Arrays were interrogated with the indicated MFCs (high dose) and the MTX-PEG
“universal control.” Images from each 96-well format array screen (one compound per array) were clustered to yield the composite image
shown here.
B-MFC. The right panel summarizes array results ob- marized in more detail in Figure 4, revealed numerous
interaction events for purvalanol B-MFC. Noteworthy istained with the extended list of kinases. Overall scoring
of the array results obtained at both high and low dose that all candidate targets identified in the cDNA library
screens were kinases (Figure 3B, left panel). These in-of MFCs is summarized in Figure 4.
Analysis of the array images shown in Figure 3B, sum- cluded a subset of the known targets for purvalanol B,
Figure 2. Synthesis and Characterization of Kinase Inhibitor Hybrid Ligands
(A) Structures and enzyme inhibitory properties of parent compounds and MFCs.
(B) Comparable cellular uptake/functionality of MFCs. Competitive inhibition of “reference”-MFC-induced HIS3 reporter activation (reflected
by a decrease in yeast growth) in response to increasing concentration of test MFCs (n  3 independent experiments).
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Figure 4. Summary of Higher-Resolution
Y3H Kinase-Array Analysis
Experiments were performed as shown in
Figure 3B. In addition, MFCs were used at
both high dose (spotting of 1 l of a 5 mM
solution) and low dose (spotting of 1 l of a
0.5 mM solution). Instances in which a signal
was detected only at the high dose of com-
pound are highlighted by inclusion of an [H].
Signal intensity was scored as either strong
(3), medium (2), or weak (1). BAIAP1 is an
example of a “false positive” that produced
a signal with all compounds. Genetic count-
erscreens revealed that none of the positively
marked interactions could be detected in the
absence of either one of the hybrid proteins.
Generally used acronyms for the various ki-
nases are shown. Gray shaded boxes indi-
cate previously known purvalanol B targets.
Full name and ENSMBLE IDs for each gene
are provided in the Supplemental Data, ap-
pendix 1. This includes annotations with re-
spect to the nature of the cDNA clones/type
of fusion protein expressed in the recombi-
nant yeast strains (FL, full-length; KD, partial
ORF including the kinase domain).
i.e., CDK2 and casein kinase 1 (CK1 or CSNK1). A previ- additional nonreceptor tyrosine kinase (LCK), and one
nonprotein kinase (SUD). Collectively, a total of 35 ki-ous study that reported CK1 binding properties of purva-
lanol B did not resolve which subtypes of CK1 could nase interaction events were observed with purvalanol
B-MFC (Figure 4), 31 of which were found to involveinteract with this purine analog [20]. Here, we identified
three distinct forms of CSNK1, namely CSNK1D, novel candidate kinase targets. These results indicate
that the target spectrum of purvalanol B is significantlyCSNK1E, and CSNK1G (all encoded by distinct genes).
Besides these known targets, several novel candidate broader than one may have anticipated, although it re-
mains to be determined what the affinity of purvalanolpurvalanol B binders were identified, including CDC/
CDK-like proteins (CLK1, CLK2, CLK3, PCTK1, PCTK2), B is for any of these targets.
Purvalanol B-MFC did not promote halo-growth ofother types of serine/threonine kinases (PAK4, RSK3),
nonreceptor tyrosine kinases (FYN, YES), and, interest- yeast cells when either the DBD- or AD-fusion proteins
were absent (see Figure 4 legend, genetic coun-ingly, receptor tyrosine kinases (EPHB2, EPHB4, FLT4,
TRK-B; in each case the cytoplasmic domain, which terscreens). Also, none of the kinases scored positively
with the control compounds MTX-PEG5-OCH3 (“univer-encodes the RTKs kinase domain, was encoded by the
selected cDNA). The extended kinase array analysis sal control”) and GPC 285937 (DEX control). These con-
trol tests indicate that all the putative purvalanol B-MFC(Figure 3B, right panel) revealed an additional 18 positive
interaction events, which included two other known tar- Y3H interaction events are likely to reflect a specific and
direct interaction of target with purvalanol B. Further-gets for purvalanol B, CDK1, and CDK5 (Figures 3B
and 4). Interestingly, a weak but significant signal was more, most of the kinases did not score positively with
the MFC of the methylated, CDK-inactive form of purva-observed consistently also with CDK4, which is inhibited
by purvalanol B in vitro at micromolar IC50 (see Figure lanol B (Me-purvalanol B, GPC286207). Those kinases
that did score positively, i.e., CSNK1, CLK1, PAK4, and2A). The 15 additional novel interaction events (exclud-
ing CDK4) included several additional CDC/CDK-related PKWA, appeared to have a significantly lower apparent
affinity for Me-purvalanol B as compared to purvalanolkinases (CDK3, CDK9, CCRK, CLK4, PCTK3), other
types of serine/threonine kinases (GSK3A, PKWA, B, as suggested by the significantly lower halo-signal
intensity observed at the high dose of compound andCSNK2A2, AKT1, MSK1, PRKCG, CAMK2A, SNRK), one
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the complete lack of signal at the lower dose of com-
pound (see Figure 4 for overall scores). In summary, the
results presented in Figure 4 reveal a broad spectrum
of candidate targets for purvalanol B and indicate that
overlapping structural requirements dictate the interac-
tion of the CDK-active form of purvalanol B with its
known and newly identified candidate interactors.
The target spectrum outlined in Figure 4 included a
number of known targets of purvalanol B but not all (i.e.,
CDK7, ERK1, ERK2). Also, for a few of the known targets,
the presumed “interaction strength” (as reflected by the
extent of yeast growth/Y3H halo-signal) did not correlate
well with the known potency of purvalanol B toward
these targets (CDK1, CDK5). This is not surprising, given
that a number of factors may govern detection of an
interaction event. These include but are not limited to
the following factors. (1) Variability in AD-fusion protein
expression, folding, and nuclear translocation (e.g.,
CDK1 expression could barely be detected, in contrast
to CDK2 and CDK4; data not shown). (2) Affinity for
a small molecule may be influenced or dependent on
accessory/regulatory factors (e.g., p25/p35; the CDK5
cyclin is primarily expressed in brain and is required
for activation of CDK5 [32–34]. Yeast cyclins may not
complement p25/p35 function. Active CDK7 requires
three components, CDK7, cyclinH, and MAT). (3) Affinity
of the AD-fusion protein for the small molecule may be
close to the presumed detection limits of Y3H (see be-
low, e.g., ERK1 and ERK2 are inhibited by purvalanol B
with IC50s in the micromolar range). (4) Positioning of
Figure 5. Differential Interaction of Purine Analogs with CK1 Sub-the PEG-spacer may affect interaction of a small mole-
typescule with different target proteins differentially. (5) When
(A) Yeast halo-analysis at high and low dose of MFC.performing a cDNA library screen, presence and relative
(B) Western blot analysis (blotting for anti-HA-tag) of CK1 subtypeabundance of a particular cDNA in a given cDNA library
AD-fusion proteins expressed in yeast. PGK (phospho-glycerate-and the redundancy at which a screen is performed
kinase) was included in the analysis to control for sample loading.
will also influence the extent to which targets can be
identified.
lanol B has higher affinity for CSNK1E and G than ros-
covitine, at least in the context of Y3H. In contrast,
drawing conclusions with respect to potential differ-Comparative Array-Based Y3H Screening
with Kinase Inhibitors ences in relative binding affinities of a given compound
for one or the other target is more speculative, givenAs described in the previous section, replica yeast cell
array screening can provide a useful approach to target the variables associated with expression, folding, and
translocation of fusion proteins in yeast. However, if oneprofiling and comparative analysis of small molecules.
Features distinguishing even closely related com- controls for protein expression levels, it may be possible
to tentatively rank closely related targets according topounds can be revealed by this approach. This is further
highlighted by the comparative analysis performed with observed “interaction strength.” For instance, as shown
in Figure 5B, both CSNK1D and CSNK1E seem toMFCs derived from the purine analogs purvalanol B and
roscovitine, the indenopyrazole IP1, and derivatives of achieve similar expression levels in yeast. However, at
low dose of compound, roscovitine-MFC scored withthese compounds (Figures 3B and 4). Replica arrays
including the 38 selected kinases were interrogated with CSNK1D but not CSNK1E, suggesting that CSNK1D
could be a higher-affinity target. More studies will bethe respective MFCs. Roscovitine-MFC scored posi-
tively with its known target CDK2. Interestingly, it also necessary to evaluate the extent to which such correla-
tions can be made with any level of confidence. Likescored positively with CSNK1D and CSNK1E but, in con-
trast to purvalanol B, not with CSNK1G. Figure 5A shows purvalanol B-MFC, roscovitine-MFC also scored with
PCTK1 and comparatively weakly with CLK1, PAK4,that the differential behavior of these closely related
purine analogs becomes even more pronounced when GSK3a, PCTK3, and PKWA. Hence, roscovitine-MFC ap-
pears to have a more restricted Y3H-target profile thanscores at low dose are considered. Purvalanol B-MFC
scored positively with all three CK1 isotypes, whereas purvalanol B-MFC. Comparatively, the indenopyrazole
IP-1-MFC recognized a broader spectrum of targets. Itroscovitine-MFC only scored with CSNK1D. Given that
both the purvalanol B and roscovitine MFCs displayed scored positively with its known targets CDK1, CDK2,
and CDK4. In addition, the IP-1-MFC interaction profilea comparable “cellular uptake”/DHFR binding competi-
tion profile (Figure 2B), these results suggest that purva- extended to other CDC/CDK-related kinases and other
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types of serine threonine kinases (Figures 3B and 4). RSK-3, FYN, YES, and LCK. Enzyme inhibition at 1 M
purvalanol B was greater than 50% in each case, sug-These targets have not been described previously for
any indenopyrazole. The CDK-inactive IP-1*-MFC did gesting that IC50 values for these kinases likely range
below 1 M. In summary, with respect to targets identi-not score positively with any of the kinases, except
weakly with CLK1, indicating that overlapping structural fied in cDNA library screens, 12 of 16 novel candidate
targets scored positively in at least one secondaryrequirements dictate interaction of the CDK-active form
of IP-1 with its known targets and most of the newly assay. In total, 22 novel interactions were confirmed by
at least one secondary assay.identified kinase targets. Thus, as for MFCs of purvalanol
B and roscovitine, IP1-MFC appears to have a more
extended target profile than one may have anticipated,
Discussionespecially considering the putative associations with
kinases other than cell cycle kinases.
The ease with which recombinant yeast cells can be
generated and manipulated in the laboratory has greatly
contributed to the success of the development and ap-Biochemical Analysis and Validation
of Y3H Interactions plication of yeast two-hybrid systems to mapping of a
wide range of different protein-protein interactions onTo further scrutinize the extent to which positive Y3H
scores are likely to reflect bona fide small molecule- a proteomic scale [7]. In the present study, we explored
the potential of a related yeast-based molecular interac-protein interactions, we evaluated the ability of purvala-
nol B to interact in vitro with targets identified by Y3H. tion system, Y3H [1], for the discovery of novel small
molecule-protein interactions and evaluated variousA representative sample of interactions was evaluated
that included known and novel candidate interactors. screening approaches with MTX-based hybrid ligands
incorporating small molecule kinase inhibitors. BothThe analysis included the following: (1) in vitro enzyme
assays with purified kinases and (2) affinity chromatog- cDNA library and focused screening of yeast cell arrays
displaying selected polypeptide ORFs led to the identifi-raphy assays to detect binding of cellular proteins to
immobilized purvalanol B (but not Me-purvalanol B). cation of known targets as well as many novel candidate
targets. As shown for the purine analog purvalanol B,PEGylated purvalanol B (intermediate A, R  H, Figure
2A) was directly coupled to solid phase, as previously many of the interactions involving putative novel kinase
targets could be confirmed by either one or more sec-described [20], incubated with cell extracts, and bound
proteins were eluted and subjected to analysis. For the ondary in vitro binding or enzyme inhibition assays, indi-
cating that a significant proportion of interaction eventsdetection of endogenous proteins, cellular extracts de-
rived from Jurkat cells were used. The identity of bound observed with the Y3H assay system described herein
do reflect, or are likely to reflect, bona fide small mole-proteins was determined by either LC-MS analysis (liq-
uid chromatography-mass spectrometry) or immunoblot cule-protein interactions. Based on these findings, we
conclude that Y3H is a powerful method for scanninganalysis using commercially available “antitarget” anti-
bodies. In a complementary approach, extracts derived of the proteome for candidate small molecule kinase
inhibitor targets.from transiently transfected 293 cells were used to
detect binding of myc-tagged kinase/kinase domain- Prior to this study, it was unclear whether expression
of various kinases would interfere with yeast growth andencoding polypeptides by immunoblot analysis using
an anti-myc-tag antibody. thus be incompatible with Y3H. The results we obtained
suggest that many different types of kinases can beFigure 6 shows examples of typical immunoblot ex-
periments. Specific binding to immobilized purvalanol B expressed as fusion proteins in yeast in a form suitable
for interaction with small molecule ATP-competitive ac-was detected for a number of endogenous or exogenous
kinases, including the novel candidate targets CDK9, tive site kinase inhibitors. Interestingly, in several instances
we noticed that in the presence of compound the steady-PCTK1, CLK3, GSK3a, CSNK1D, MSK1, EPHB2, and
FLT4 (the approach was also validated by including anal- state levels of kinase fusion proteins increased (data not
shown), an effect that is likely to facilitate the detectionysis of known targets, such as CDK1, CDK2, CDK5,
CDK7, ERK1, and ERK2). No binding to immobilized of certain interactions. Either full-length open reading
frame (ORF) or partial ORF-encoding polypeptides en-Me-purvalanol B or PEG-spacer alone was detected.
Expression of some targets was barely or not at all compassing kinase domains may be suitable or even
required for productive interactions to occur in Y3H,detectable (AKT1, CLK1, PKWA, SNRK) and hence failed
to be reconfirmed by this approach. As shown in Figure depending on the type of kinase (e.g., not surprisingly,
only the cytoplasmic domains of receptor tyrosine ki-7, several additional Y3H-identified targets were de-
tected by affinity chromatography/LC-MS analysis of nases were identified). Hence, high quality, complex
cDNA libraries encoding multiple fusion proteins ofJurkat cell extracts (i.e., detection of endogenous pro-
teins), including the novel candidate targets CDK3, candidate targets are an important factor in Y3H screen-
ing, which is reminiscent of the well-established obser-CDK9, CCRK, PCTK2, PCTK3, CSNK1D, CSNK1E,
CSNK2A2, CAMK2G, PAK4, RSK-3, FYN, YES, and LCK vations that complex protein-domain-encoding cDNA
libraries are a major contributor to successful Y2H(known targets, e.g., CDK1, CDK5, ERK1, and ERK2,
were also identified). No binding to immobilized Me- screening for the detection of protein-protein interac-
tions.purvalanol B was detected for any of the kinases. As
also shown in Figure 7, several novel interactions were Judging from the range of interactions identified in this
study, the sensitivity limit of Y3H appears comparable toconfirmed using in vitro enzyme assays, including CDK3,
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Figure 6. In Vitro Binding of Purvalanol B to Novel Candidate Targets
In vitro binding of cellular proteins from Jurkat cells (endogenous proteins) or 293 cells (exogenous, myc-tagged proteins) to bead-immobilized
purvalanol B. Protein binding was detected by immunoblot analysis using antibodies directed against endogenous proteins or the myc-tag
of transgene-encoded fusion proteins, as indicated. Immobilized, Me-purvalanol B and PEG-spacer alone served as controls, as indicated.
Very weak or no significant protein expression was detected for AKT1, CLK1, PKWA, and SNRK.
that of Y2H [35] (low-micromolar affinity interaction). For most suitable for a “yes or no” detection of an interac-
tion, with a presumed limit for detection of low-micromo-instance, purvalanol B-MFC detected CDK1, CDK4 and
CK1, while roscovitine MFC detected CDK2. Purvalanol lar affinity type of interactions. Thus, although the kinase
inhibitor screens performed in this study revealed aB and roscovitine inhibit these enzymes in vitro with IC50
values in the higher nanomolar to low micromolar range. number of interesting novel candidate targets, the phar-
macological relevance of these interactions remains toThus, the sensitivity of Y3H ought to be adequate for
detection of many molecular interactions of pharmaco- be determined. Ranking such interactions by affinity cri-
teria would provide an important next step and furtherlogical interest. Y3H signal intensity may, however, not
adequately reflect differences in relative affinity of a facilitate the prioritization of targets for functional valida-
tion. For instance, the question of whether inhibition ofsmall molecule for different targets, given that factors
other than ligand-protein affinity may affect readout, certain CK1 subtypes by the purine analogs purvalanol B
and roscovitine plays an important role in the antitumorsuch as protein expression, folding, and nuclear translo-
cation, or positioning of the PEG-spacer/linker on the activity of these compounds (and potentially other pu-
rine analogs) warrants further investigation, especiallytest compound. Thus, Y3H analysis appears generally
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Figure 7. Summary of Biochemical Analysis
of Purvalanol B-Protein Interactions
Binding of proteins to immobilized purvalanol
B but not Me-purvalanol B was evaluated by
immunoblotting (as shown in Figure 6) or LC-
MS (for endogenous Jurkat proteins). Enzyme
assays were performed with purified en-
zymes, and percentage inhibition of kinase
activity observed with 1 M purvalanol B is
shown (data provided by Upstate Inc.).
when considering that R-roscovitine (also known as pounds that would compete for binding to that target,
although this type of assay would be more suitable inCYC202) has entered phase I/II human oncology clinical
trials as a CDK2 inhibitor [23, 24]. the context of mammalian cells, given the natural perme-
ability barrier displayed by yeast cells to (nonhybrid)Scanning of focused gene/protein families (e.g., ki-
nases) or selected ORF collections may be pursued us- small molecules. A recent, elegant study reported the
use of a Y3H-based assay for the identification of pro-ing yeast cell array screening, as exemplified in this
study by the kinase array analysis. The array screening teins with chemical bond-cleaving properties [39], pro-
viding an example of application to enzyme catalysis.approaches described in this study made use of 96-
well array formats, and currently available robotics can The present study indicates that Y3H can be applied to
the discovery of novel candidate drug targets, providingsupport the analysis of hundreds to thousands of inter-
action events in a period of a few days. These screening an alternative or complement to current approaches in
small molecule mechanism of action studies.formats have therefore the potential to enable rapid
comparative screening of small molecules and the char-
acterization of interactions of small molecules with tar- Significance
gets for which standard or routine enzyme or biochemi-
cal assays are not readily available. Scanning of the The identification of protein targets of organic small
molecules is a critical step toward an understandingproteome may be approached using cDNA-library
screening. This screening format represents a more ran- of the molecular basis of drug efficacy and side effects.
Unfortunately, the identification of such targets re-dom approach to target discovery that may lead to valu-
able insights into the molecular basis of drug action. mains a current major bottleneck both for drug discov-
ery and chemical genetic studies. We have developedThe Y3H system described herein may conceivably also
be used to find novel ligands for targets. For instance, a generic Y3H-based compound-protein binding assay
and screening approaches that enable the identifica-focused small molecule hybrid ligand libraries could
possibly be used to screen for target binding properties tion of targets of small molecules kinase inhibitors, an
important class of pharmaceutical agents. The sys-by parallel array profiling of a selected group of candi-
date targets. Alternatively, a specific hybrid ligand-tar- tematic screening approaches described in this study
should be applicable to mechanism of action studiesget assay could arguably be used to screen for com-
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Array Screeningusing other types of organic small molecules, and thus
Plasmids encoding targets of interest were transformed into theof broader relevance to drug discovery.
strain L40 or strain 6A containing the pBYK-DHFR plasmid. Cotrans-
formants were selected, the culture expanded and subsequently
Experimental Procedures
distributed in a 96-well MTP. A high and a low amount of MFC was
applied (1 l of a 5 mM solution or 1 l of a 0.5 mM solution) onto
MFC Synthesis
several omni trays (Nunc, FRG) containing selective media. Onto
Details of the MFC synthesis (e.g., purvalanol B-MFC, GPC286076)
each spot, a small aliquot of yeast cells (7 l) was added. Growth
are provided in the Supplemental Data (appendix 3).
of yeast was determined after an incubation of 3 days at 30C. A
genetic counterselection method was used to test the dependence
Bacterial and Yeast Strains of the reporter activation on the expression of both fusion proteins.
E. coli strain DH10B (Life Technologies, UK) was used for all bacterial The plasmid pBYK encodes for the dominant-negative selection
work in this study. The Saccharomyces cerevisiae strains used in marker CYH2, enabling active plasmid loss on media containing
this study were either L40 (Invitrogen, NL; Mat-, his3-200, trp1- cyclohexamide. To test for DHFR-independent activation, all ar-
901, leu2-3,112, ade2, LYS2::(4lexAopHIS3), URA3::(8lexAopLacZ), rayed yeast colonies were tested for reporter activation in the pres-
GAL4) or the derivative strain 6A (GPC Biotech; MATa, his3-200, ence of MFC on plates lacking leucine and histidine and containing
trp1-901, leu2-3,112, LYS2::(4lexAopHIS3), ade2::(6lexAopURA3), 1 g/ml cyclohexamide [40]. To test for AD-fusion protein indepen-
ura3::(8lexAopLacZ), GAL4, gal80, can1, cyh2). Both strains enable dent activation, a strain expresssing only the pBYK-DHFR fusion
the use of a LexA BD-based protein interaction system using the protein was tested with MFC on media lacking tryptophane and
HIS3 and/or LacZ reporters and the use of commercial cDNA librar- histidine.
ies fused to the GAL4p activation domain. Yeast cells were grown
in synthetic dextrose (SD) media with appropriate auxotrophic sup-
Plasmid Isolationplements [36]. Standard genetic methods were followed.
Plasmids were isolated from yeast cells using the QIAprep96 Turbo
Miniprep Kit (Qiagen, NL). Cell material was directly taken from
Plasmids selective agar trays, resuspended in buffer 1 supplemented with
The E. coli dihydrofolate reductase-encoding gene was amplified zymolyase at a final concentration of 0.4 mg/ml, and incubated
using the following primers: DHFR-1 (5-GGGGGTCGACATGATCA at 37C for 60 min. After this preincubation, the manufacturer’s
GTCTGATTGCGGCGTTAGCG-3) and DHFR-2 (5-GGGGGCGGC protocol was followed. One tenth of the eluted DNA was transformed
CGCTTACCGCCGCTCCAGAATCTCAAAG-3), using a genomic bac- into electro-competent E. coli cells using standard procedures. Am-
terial library (Clonetech, Palo Alto, CA) as a template. The PCR picillin-resistant colonies were selected, amplified, the plasmids
product was digested with SalI and NotI and subcloned into pBYK were isolated, and cDNA inserts were sequenced and identified
(GPC-Biotech), resulting in the vector pBYK-DHFR encoding a LexA using standard databases and blast algorithms.
(DBD)-DHFR fusion protein. pBYK is a variation of pBTM117c [40],
in which a kanamycin-resistance gene replaces the -lactamase
Competition Experimentsgene.
The invariable component of all MFCs, the “anchor,” is MTX. This
shared feature was used to set up competition experiments in yeast
cDNA Libraries
cells in which competition for binding of a test MFC with a “refer-
Strain 6A  pBYK-DHFR was transformed using the lithium acetate
ence” MFC to DHFR was determined. IP-1 was used as a reference
method [37] with any of the following pACT2-cDNA libraries pur-
MFC. A specific protein domain of human BAP28 (Q9H583), which
chased from Clontech, Palo Alto, CA.: human brain, liver, heart,
was found to bind specifically to IP-1 in the Y3H assay, was used
placenta, and testis. Alternatively, oligo-dT primed, directionally
as an AD-fusion protein. Interaction induced a strong activation of
cloned cDNA libraries (derived from human testis, HeLa and B-cell
the HIS3 reporter gene. Competitive binding to DHFR of a test MFC
lymphoma line K562 mRNA) were generated via SalI-NotI adaptor-
is reflected in a reduction of IP-1-MFC-induced reporter activation.
based cloning using a Superscript cDNA library construction kit
A “growth” dose-response experiment was performed for each test
following manufacturer’s instructions (Invitrogen). The cDNAs were
MFC using serial dilution of the test compounds and a fixed amount
subcloned into the SalI-NotI linerazied yeast shuttle vector pUACH.
of IP-1-MFC. For each data point, 2 	 105 yeast cells expressing
pUACH is based on the plasmid pGAD425 [41] with the addition of
the DBD-DHFR and the AD-BAP28 fusion proteins were incubated
the CYH2 expression cassette which confers sensitivity to cyclohex-
in standard liquid culture medium lacking histidine in a total volume
imide [42]. All libraries encoded polypeptides fused to the carboxyl
of 150 l, to which were added 1 l 0.5 mM IP-1-MFC and 1 l 0.4
terminus of the GAL4 activation domain. The total number of inde-
mM MTX. To test for growth competition, either 1 l of DMSO
pendent yeast colonies reflected at least 1	 the complexity of inde-
(negative control, 100% growth) or 1 l of test MFC were added.
pendent clones documented for the E. coli library, as specified by
Yeast cell growth was monitored and quantified by measuring the
the manufacturer. The yeast libraries were harvested, quality control
optical density of the culture at day three at a wavelength of 600 nm.
tested, and stored in small aliquots at 
70C.
A different reference MFC was used for IP-1 comparative analysis.
cDNA Library Screening
Enzymatic AssaysMFC (final concentration 4–8 M) was spread evenly onto screening
The appropriate kinases and cyclins were expressed in Sf9 insectQ-trays (Genetix, UK) with SD-agar lacking leu, trp, and his. A pre-
cells. CDK/cyclin complexes were purified and assayed as de-transformed yeast library was applied onto the plates with a density
scribed previously [28].of approximately 5 	 107–1 	 108 cells per tray. For a complex
mammalian cDNA library screen, five Q-trays were screened. Even
distribution of compound and yeast cells on the medium was en- Preparation of Cell Extracts
cDNAs were cloned into pCMV-Tag3 vectors (Stratagene). Jurkatsured by distribution of the liquid with sterile 5 mm glass beads.
Resulting colonies were transferred into 96-well flat bottom MTP’s cells or 293 cells were propagated following standard protocols.
293 cells were transfected with pCMV-Tag3 vectors encoding myc-(Nunc, FRG) containing SD medium lacking leu and trp and con-
taining 1 M betaine and incubated at 30C for 3 days. For array tagged proteins using Effectene Transfection Reagent (QIAGEN,
301425). Cells were propagated for 40 hr under normal growth condi-specificity testing, a 20 l aliquot of yeast cells grown in a 96-well
microtiter plate was spotted twice onto screening Q-trays using a tions. Whole-cell extracts were prepared following a protocol
adapted from Romero et al. [38] and either stored at 
80C or usedrobotic liquid handling system (MultiPROBE II, Packard Bioscience).
One microliter of compound of interest (5 mM or 0.5 mM stock directly for pull-down assays. Yeast extracts were generated by
lysis of the cells with NaOH and 50% trichloroacetic acid. The pro-solutions) was spotted in the center of the cell spot. The trays were
incubated for 2 days at 30C, and compound-dependent growth teins were precipitated with ice-cold acetone and resuspended in
sample buffer.was determined.
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Pull-Down sion for synthetic organic chemistry. Bioorg. Med. Chem. 6,
1127–1152.Modified purvalanol B and methylated purvalanol B (5 PEG-amine
spacer) were coupled to ReactiGel agarose beads (Pierce, No 20259) 9. Clackson, T. (2000). Regulated gene expression systems. Gene
Ther. 7, 120–125.as previously described [20]. The final concentration of compound
on the resin ranged between 10 and 50 mol/ml. Pull-downs were 10. Pollock, R., and Clackson, T. (2002). Dimerizer-regulated gene
expression. Curr. Opin. Biotechnol. 13, 459–467.essentially performed as previously described [20]. Ten microliters
of packed gel and 90 l cell extract were used for immunoblotting 11. Lin, H., Abida, W., Sauer, R., and Cornish, V.W. (2000). Dexa-
methasone-methotrexate: an efficient chemical induced of pro-experiments or 40 l gel and 360 l cell extract for LC-MS experi-
ments. tein dimerization in vivo. J. Am. Chem. Soc. 122, 4247–4248.
12. Abida, W.M., Crater, B.T., Althoff, E., Lin, H., and Cornish, V.W.
(2002). Receptor-dependence of the transcription read-out in aLC-MS Analysis
small-molecule three-hybrid system. Chembiochem 3, 887–895.Tryptic digestion was performed with sequencing grade trypsin
13. Baker, K., Sengupta, D., Salazar-Jimenez, G., and Cornish, V.W.(Roche, 1 418 025) following the manufacturer’s instructions, and
(2003). An optimized dexamethasone-methotrexate yeastthe resulting peptide mix was concentrated prior to LC-MS analysis.
3-hybrid system for high throughput screening of small mole-Peptides were separated on a PepMap C18 column on a nano-LC
cule-protein interactions. Anal. Biochem. 315, 134–137.apparatus (Ultimate, Dionex) and submitted to MS/MS on an ESI-
14. Henthorn, D.C., Jaxa-Chamiec, A.A., and Meldrum, E. (2002). Aion trap MS (Esquire 3000 plus, Bruker Daltonics). Proteins were
GAL4-based yeast three-hybrid system for the identification ofidentified using the Mascot database search engine (Matrix
small molecule-target protein interactions. Biochem. Pharma-Science).
col. 63, 1619–1628.
15. Manning, G., Whyte, D.B., Martiniez, R., Hunter, T., and Sudarsa-Immunoblot Analysis
nam, S. (2002). The protein kinase complement of the humanProteins bound to the compound resin were recovered with sample
genome. Science 298, 1912–1934.buffer (Roth, K929.1) heated at 95C for 5 min, separated on SDS-
16. Chang, Y.T., Gray, N.S., Rosania, G.R., Sutherlin, D.P., Kwon,PAGE, and submitted to immunoblotting analysis. Detection was
S., Norman, T.C., Sarohia, R., Leost, M., Meijer, L., and Schultz,performed using ECL reagent (Amersham, RPN2106), as suggested
P.G. (1999). Synthesis and application of functionally diverseby the manufacturer. Antibodies used in this study are listed in the
2,6,9-trisubstituted purine library toward the development ofSupplemental Data (appendix 2).
functionally diverse CDK inhibitors. Chem. Biol. 6, 361–375.
17. Knockaert, M., Greengard, P., and Meijer, L. (2002). Pharmaco-Supplemental Data
logical inhibitors of cyclin-dependent kinases. Trends Pharma-Supplemental Data including experimental procedures for the syn-
col. Sci. 23, 417–425.thesis of purvalanol B MFC (GPC286076), full name/ENSMBLE IDs
18. Davies, T.G., Bentley, J., Arris, C.E., Boyle, F.T., Curtin, N.J.,for all kinase targets, and a description of all antibodies used in this
Endicott, J.A., Gibson, A.E., Golding, B.T., Griffin, R., Hardcastle,study is available at http://www.chembiol.com/cgi/content/full/11/
I.R., et al. (2002). Structure-based design of a potent purine-2/211/DC1.
based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 9,
745–749.
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